Targeting the c-Myc coiled coil with interfering peptides

Eva M Jouaux1, Karin Schmidtkunz, Kristian M Müller

  • 1Institute for Biology III, Albert-Ludwigs University of Freiburg, Schaenzlestrasse 1, Freiburg, Germany.

Insights

Targeting the oncogene c-Myc, researchers developed interfering peptides that disrupt its crucial dimerization with Max. These peptides show promise for cancer therapy by inhibiting c-Myc activity and DNA binding.

Area of Science:

  • Oncology
  • Molecular Biology
  • Protein-protein Interactions

Background:

  • c-Myc is a frequently deregulated oncogene in human cancers.
  • Inactivation of Myc can induce tumor regression, presenting a therapeutic opportunity.
  • Myc's function relies on dimerization with Max, a key target for intervention.

Purpose of the Study:

  • To develop novel interfering peptides targeting the Myc:Max interaction.
  • To evaluate the efficacy of these peptides in disrupting Myc function and DNA binding.

Main Methods:

  • Applied two strategies: a dominant-negative Max sequence and a peptide (Mip) from a genetic library.
  • Fused peptides to acidic extensions to interact with Myc's DNA-binding region.
  • Utilized a protein-fragment complementation assay for peptide selection.

Main Results:

  • Both Max and Mip peptides effectively outcompeted the Myc:Max interaction.
  • Interfering peptides successfully inhibited the DNA binding of the Myc:Max complex.
  • Peptides showed increased thermal stability (T(m)) upon interaction with Myc.

Conclusions:

  • The developed interfering peptides (Max and Mip) effectively inhibit human Myc:Max activity.
  • These peptides are promising tools for analytical and therapeutic research targeting Myc in cancer.

Related Concept Videos